FDA Flags Safety Risks of Fatty Liver Treatment

Published on May 17, 2023

The U.S. health regulator’s staff reviewers on Wednesday raised a string of concerns with Intercept Pharmaceuticals’ treatment for a type of fatty liver disease, sending the drugmaker’s shares plunging 22%. The U.S. Food and Drug Administration’s reviewers flagged increased…

Read Full Article (External Site)